Latest Breaking News On - சோதனை வலைப்பின்னல் - Page 9 : comparemela.com

INOVIO s VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18

Share this article Share this article PLYMOUTH MEETING, Pa., Jan. 6, 2021 /PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and HPV-associated diseases, today announced positive efficacy results for an open-label Phase 2 trial of VGX-3100 to treat HPV-16 and HPV-18-associated vulvar dysplasia. A 25% or more reduction in HPV-16/18-associated vulvar HSIL (high-grade squamous intraepithelial lesion) was observed for 63% of trial participants (12 of 19) treated with VGX-3100 at six months post-treatment. Three out of the 20 participants with histology data (15%) resolved their vulvar HSIL and had no HPV-16/18 virus detectable in the healed area. By comparison, the spontaneous resolution of vulvar HSIL caused by HPV-16/18 is estimated to be only 2%. The trial also showed VGX-3100 to be safe and well-tolerated. Based upon these results INOVIO is planning

Ben matonePrakash bhuyanJeff richardsonMilton lawrence mccallRobert edwardsKaneka eurogentecWalter reed army institute of researchUs department of defenseNational cancer instituteNational institute of allergyPlumbline life sciencesTherapeutic clinical developmentMelinda gates foundationCoalition for epidemic preparedness innovationsGynecology reproductive sciencesUniversity of pittsburgh

Orange County s UCI Health opens mobile field hospital to handle coronavirus surge

Orange County s UCI Health opens mobile field hospital to handle coronavirus surge UCI Health administrators say they ve been preparing to deal with a post-holiday surge of COVID-19 cases for the last six months. KABC ORANGE, Calif. (KABC) Twenty-two patients were receiving medical care as of Wednesday morning at a mobile field hospital outside UCI Health. Administrators at UCI Health said they ve been preparing for it over the last six months - a surge in COVID-19 cases after holiday gatherings. Dr. Sebastian Schubl was named the medical director of the facility. We ve seen an unrelenting rise in the number of admitted COVID patients for weeks now, Schubl said in a press conference Wednesday.

United statesLowell gordonSebastian schublTesting networkOrange county health care agencyFamilies togetherOrange countyEyewitness newsஒன்றுபட்டது மாநிலங்களில்லோவெல் கோர்டந்சோதனை வலைப்பின்னல்குடும்பங்கள் ஒன்றாகஆரஞ்சு கவுண்டிநேரில் பார்த்தவர் செய்தி

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet s EClinicalMedicine

PLYMOUTH MEETING, Pa., Dec. 24, 2020 /PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases

South koreaBen matonePablo tebasStanley plotkinJeff richardsonKaneka eurogentecJ joseph kimWalter reed army institute of researchUs department of defenseNational cancer instituteNational institute of allergyPlumbline life sciencesCoalition for epidemic preparedness innovationsUniversity of texasHospital of the university pennsylvaniaDefense consortium

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in Th

Search jobs 24-Dec-2020 INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet s EClinicalMedicine PLYMOUTH MEETING, Pa., Dec. 24, 2020 /PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the publication of peer-reviewed Phase 1 clinical data from the first cohort of 40 participants for its COVID-19 DNA vaccine candidate, INO-4800, in EClinicalMedicine, an open access clinical journal published by The Lancet. The paper, titled Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, Phase 1 clinical trial, found that INO-4800 was immunogenic in all vaccinated subjects, effectively generating an immune response of humoral (including neutralizing antibodies) and/or cellular re

South koreaBen matonePablo tebasStanley plotkinJeff richardsonKaneka eurogentecJ joseph kimWalter reed army institute of researchUs department of defenseNational cancer instituteNational institute of allergyPlumbline life sciencesLaval universityMelinda gates foundationCoalition for epidemic preparedness innovationsUniversity of texas

В Беларуси завершено масштабное тестирование технологии 5G_Russian news cn

В Беларуси завершено масштабное тестирование технологии 5G_Russian news cn
russian.news.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from russian.news.cn Daily Mail and Mail on Sunday newspapers.

Belarus generalLatest networkBrest regionபெலாரஸ் ஜநரல்சோதனை வலைப்பின்னல்ப்ரெஸ்ட் பகுதி